Healthcare Industry News: ascites
News Release - April 5, 2022
Bearpac Medical Announces CE Mark Certification for the Passio(TM) Pump Drainage System
MOULTONBOROUGH, N.H., April 5, 2022 -- (Healthcare Sales & Marketing Network) -- Bearpac Medical, LLC is pleased to announce that it has received CE Mark certification for use of the Passio Pump Drainage System with indications for the intermittent drainage of recurrent and symptomatic pleural effusions and malignant ascites.The Passio Pump Drainage System consists of the Passio Catheter, a Handheld Control Unit (pump) and a Disposable Collection Kit, which includes a redressing kit, for drainage of recurrent and symptomatic pleural effusions and malignant ascites. The Passio pump is attached to an implanted Passio catheter using the disposable collection kit and is activated to begin the evacuation of fluid into the collection bag. The Passio catheter is exclusively designed for use with the Passio collection system. Passio provides flow control throughout the therapy at lower vacuum pressures than competitive devices on the market today.
"As Bearpac builds on our product offering, the CE Mark for the Passio system is another important milestone. This new indication and expansion to CE provides Bearpac with an opportunity to now introduce Passio to patients and physicians around the globe," said Jay Zimmerman, President of Bearpac Medical.
The CE Mark confirms that Passio meets quality standards for design, manufacture and final inspection. The certification enables Bearpac Medical to market Passio in European Economic Area (EEA) member countries as the company explores expansion opportunities in Europe as part of its global strategy.
About Bearpac Medical, LLC
Bearpac Medical is a privately held medical technology company headquartered in New Hampshire, focused on the development of novel thoracic drainage products to improve the lives of patients experiencing pleural effusions and malignant ascites. For more information, please visit www.bearpac.com.
Source: Bearpac Medical
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
